Ocugen’s Strategic Pivot Sets Stage for Critical Year
As 2025 concludes, Ocugen has solidified a sharpened strategic direction. The biotech firm’s shares have demonstrated notable resilience, trading consistently above the crucial $1 threshold...
Analysis
